Mirati Therapeutics (MRTX) 10-K 2016 FY Annual report

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-3 No. 333-207848) of Mirati Therapeutics, Inc.,

(2) Registration Statement (Form S-3 No. 333-206965) of Mirati Therapeutics, Inc.,

(3) Registration Statement (Form S-3 No. 333-198678) of Mirati Therapeutics, Inc., 

(4) Registration Statement (Form S-8 No. 333-204720) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc.,

(5) Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc., and

(6) Registration Statement (Form S-8 No. 333-196487) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics Inc.;

of our report dated March 9, 2017, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2016.

	/s/ Ernst & Young LLP
San Diego, California
March 9, 2017